---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-022267"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T11:59:16.881908+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ionis CDO Richard Geary retiring Jan 2026; Holly Kordasiewicz to succeed

## Summary
- Richard Geary, EVP & chief development officer, will retire effective January 2026 after 30 years at Ionis.
- Holly Kordasiewicz, currently SVP neurology, to become EVP & chief development officer in January 2026.
- Geary led 50+ IND submissions and 6 FDA/EU approvals including TRYNGOLZA; will stay as strategic consultant in 2026.
- Kordasiewicz has 20 years R&D experience and played key role in QALSODY and IONIS-MAPT Rx Alzheimer's program.

## SEC filing metadata
- accession: 0001140361-25-022267
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/ef20050532_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-022267
- JSON: https://secwatch.observer/filing/0001140361-25-022267.json
- Plain text: https://secwatch.observer/filing/0001140361-25-022267.txt

## Key facts
- Executive change
  Holly Kordasiewicz was appointed as executive vice president and chief development officer at IONIS PHARMACEUTICALS INC.
  - Action: appointed
  - Role: executive vice president and chief development officer
  source text: On June 12, 2025, the Company issued a press release announcing that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed Dr. Richard Geary Ph.D. in the role of executive vice president and chief development officer beginning in January 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm
- Executive change
  Richard Geary retired as executive vice president and chief development officer at IONIS PHARMACEUTICALS INC.
  - Action: retired
  - Role: executive vice president and chief development officer
  source text: On June 12, 2025, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036125022267/0001140361-25-022267-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.